Connection

Jean-Charles Soria to Mutation

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Mutation.
Jean-Charles Soria
Connection Strength
0.760
Mutation
  1. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):1189-1197.
    View in: PubMed
    Score: 0.175
  2. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
    View in: PubMed
    Score: 0.166
  3. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. Eur Urol Oncol. 2020 08; 3(4):498-508.
    View in: PubMed
    Score: 0.045
  4. Osimertinib in EGFR Mutation-Positive Advanced NSCLC. N Engl J Med. 2018 03 29; 378(13):1262-1263.
    View in: PubMed
    Score: 0.042
  5. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018 03; 92:1-10.
    View in: PubMed
    Score: 0.042
  6. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034.
    View in: PubMed
    Score: 0.041
  7. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017 10; 112:62-68.
    View in: PubMed
    Score: 0.041
  8. JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. Cancer Discov. 2017 02; 7(2):128-130.
    View in: PubMed
    Score: 0.039
  9. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016 Dec; 13(12):e1002201.
    View in: PubMed
    Score: 0.039
  10. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res. 2016 Sep 01; 22(17):4309-21.
    View in: PubMed
    Score: 0.038
  11. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10; 32(2):68-75.
    View in: PubMed
    Score: 0.031
  12. Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer J. 2018 Jul/Aug; 24(4):153-162.
    View in: PubMed
    Score: 0.011
  13. Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers? Eur J Cancer. 2018 05; 94:61-69.
    View in: PubMed
    Score: 0.011
  14. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018 02; 14(2):e1005965.
    View in: PubMed
    Score: 0.011
  15. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017; 12(11):e0188174.
    View in: PubMed
    Score: 0.010
  16. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017 Jun 20; 35(18):2018-2027.
    View in: PubMed
    Score: 0.010
  17. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.